Shire, Neos Therapeutics deal
Shire granted Neos a non-exclusive license to market Neos' amphetamine polistirex XR-ODT ( NT-0202) for ADHD in the U.S. The deal settles litigation filed by Shire in April 2013 in the U.S. District Court for the Northern District of Texas Dallas Division alleging that an NDA Neos submitted to FDA for NT-0202 infringed Shire's U.S. Patent Nos. RE 42,096 and 41,148 covering Adderall XR dextroamphetamine/amphetamine to treat ADHD. Neos will pay Shire a royalty on sales of NT-0202 until the expiration of the patents. Including six months of pediatric exclusivity, the patents expire April 21, 2019. Shire reported $375.4 million in 2013 sales of Adderall XR, an extended-release formulation of Adderall, which comprises mixed salts of a single entity amphetamine. ...